1. The patient is eligible to receive Etanercept treatment according to the Austrian
SmPC.
2. The decision to treat the patient with Etanercept has been made independently by the
physician and is clearly separated from the decision to include the patient in the
study. The treatment decision was made in advance and is not dependent on the
protocol.
3. The patient was informed about the study and gave his/her consent and signed an
Independent Ethics Committee (IEC) submitted written Informed Consent form on use of
the data.
4. The patient has moderately active RA, defined as a disease activity of CDAI >10 and
≤22 and/or DAS28 (CRP)>3.2 and ≤ 5.1
1. Any contraindication according to the Austrian SmPC, which includes:
A hypersensitivity to any component of Etanercept, active tuberculosis or any other
serious infection.
2. Patient has previously participated in this study.